article thumbnail

Data hackathon analyses truth behind TB vaccine and COVID-19

pharmaphorum

Is a century-old vaccine a ‘game-changer’ for COVID-19? This is especially true in the search for effective therapies to fight COVID-19, and a vaccine. In a worst-case scenario, misplaced hype could lead to a sudden rush to buy doses of the BCG vaccine. Understanding the link between COVID-19 and the BCG vaccine.

Vaccines 110
article thumbnail

Phase 3 trial data confirm efficacy and safety profile of R21/Matrix-M malaria vaccine in African children

Express Pharma

Phase 3 trial data results of The R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India, leveraging Novavax’s Matrix-M adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. No other vaccine has reported over 55 per cent efficacy in the same age group.

Vaccines 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The power of communication: engaging diverse groups in healthcare

pharmaphorum

In the 2011 Census, 8% of the population in England listed a language other than English as their ‘first language’, and 1.3% There are a multitude of examples in the press of initiatives to change perceptions, challenge barriers and adopt a diverse and inclusive approach – blood drives, COVID19 vaccinations, cervical screening to name a few.

article thumbnail

Innovation and access: Improving Europe’s pharmaceutical regulatory framework

pharmaphorum

At the same time, personalised mRNA vaccines and CAR-T treatments are promising to revolutionise the oncology landscape. Yet when the EFPIA compared the timelines of six regulatory agencies between 2011 and 2020, it found the European Medicines Agency (EMA) “lagged behind”.

Vaccines 105
article thumbnail

Pfizer vaults into sickle cell market as GBT deal confirmed

pharmaphorum

In 2011 it paid $340 million for rights to rivipansel , a pan-selectin antagonist developed by GlycoMimetics, which failed a phase 3 test in 2019 and was jettisoned by Pfizer the following year. It’s worth noting that this isn’t Pfizer’s first deal in SCD.

Vaccines 111
article thumbnail

Biosimilars: a rapidly maturing market

pharmaphorum

The global health crisis caused spending on healthcare to increase , due to the funding provided to the development and purchases of vaccines and treatments, as well as support provided for the associated infrastructure. billion in 2020.

article thumbnail

Record number of health firms feature in UK top 100 private tech list

pharmaphorum

There are pharma companies on the list, including Kymab , which at number 87 is working with the Bill & Melinda Gates Foundation to test several potential vaccines. Also on the list is Faculty, which at number 33 provides accurate and timely information used by decision-makers in the NHS and the government.